Midatech Pharma PLC, a specialty pharmaceutical company, focuses on developing and commercializing products in oncology and immunotherapy in the United States and the United Kingdom. The company operates through two segments, Pipeline Research and Development; and Commercial. Its products include Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; Gelclair, an oral gel barrier device indicated for the management and relief of pain due to oral mucositis; Oravig, an orally dissolving buccal tablet for oral thrush; and Soltamox, an oral liquid solution of tamoxifen citrate, for the treatment and prevention of breast cancer.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+44-1235-841575
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales£1.94 million
Profitability
Miscellaneous
Employees73
Next Earnings DateN/A
OptionableNot Optionable
Midatech Pharma (LON:MTPH) Frequently Asked Questions
What is Midatech Pharma's stock symbol?
Midatech Pharma trades on the London Stock Exchange (LON) under the ticker symbol "MTPH."
How were Midatech Pharma's earnings last quarter?
Midatech Pharma PLC (LON:MTPH) released its quarterly earnings data on Thursday, September, 28th. The company reported ($19.00) earnings per share for the quarter. The firm earned $3.02 million during the quarter. View Midatech Pharma's Earnings History.
Has Midatech Pharma been receiving favorable news coverage?
News stories about MTPH stock have trended positive this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Midatech Pharma earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the next several days. View News Stories for Midatech Pharma.
Who are some of Midatech Pharma's key competitors?
Some companies that are related to Midatech Pharma include Immutep (IMM), Helix Biopharma (HBP), Imugene (IMU), Orgenesis (ORGS), Burcon NutraScience (BU), Sirona Biochem (SBM), Tiziana Life Sciences (TILS), Circassia Pharmaceuticals (CIR), Equillium (EQ), ReNeuron Group (RENE), Medicure (MPH), Pediapharm (PDP), AquaBounty Technologies (AQB), Mereo BioPharma Group (MPH) and Orthocell (OCC).
What other stocks do shareholders of Midatech Pharma own?
Who are Midatech Pharma's key executives?
Midatech Pharma's management team includes the folowing people:
- Mr. Nicholas John Robbins-Cherry, CFO, Company Sec. & Director (Age 50)
- Dr. Craig Richard Cook, CEO, COO & Director (Age 52)
- Mr. Rob Rainey FCA MBA MA, Head of Corp. Devel.
- Dr. Tim Sparey Ph.D., Chief Bus. Officer
- Mr. Justin Barry BSc (Hons.), MBIOL, CBIOL, QP, Head of Manufacturing
How do I buy shares of Midatech Pharma?
Shares of MTPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Midatech Pharma's stock price today?
One share of MTPH stock can currently be purchased for approximately GBX 5.63.
How big of a company is Midatech Pharma?
What is Midatech Pharma's official website?
How can I contact Midatech Pharma?
Midatech Pharma's mailing address is 65 Innovation Drive, Milton Park, ABINGDON, OX14 4RQ, United Kingdom. The company can be reached via phone at +44-1235-841575.
MarketBeat Community Rating for Midatech Pharma (LON MTPH)
MarketBeat's community ratings are surveys of what our community members think about Midatech Pharma and other stocks. Vote "Outperform" if you believe MTPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
